Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Changes in the Gustave Roussy Immune Score is an Important Biomarker for Therapeutic Sensitivity of Nivolumab in Gastric Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.

    Article  CAS  Google Scholar 

  2. Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017;84:212–8.

    Article  CAS  Google Scholar 

  3. Nakazawa N, Sohda M, Ubukata Y, et al. Changes in the Gustave Roussy Immune Score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12226-4.

    Article  PubMed  Google Scholar 

  4. Janjigian YY, Shitara K, Moehler M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan

    Nobuhiro Nakazawa MD, PhD, Akihiko Sano MD, PhD, Makoto Sohda MD, PhD, Ken Shirabe MD, PhD, FACS & Hiroshi Saeki MD, PhD, FACS

Authors
  1. Nobuhiro Nakazawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiko Sano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Sohda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ken Shirabe MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Saeki MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuhiro Nakazawa MD, PhD.

Ethics declarations

Disclosure

The authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakazawa, N., Sano, A., Sohda, M. et al. ASO Author Reflections: Changes in the Gustave Roussy Immune Score is an Important Biomarker for Therapeutic Sensitivity of Nivolumab in Gastric Cancer. Ann Surg Oncol 29, 7407–7408 (2022). https://doi.org/10.1245/s10434-022-12233-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12233-5

Search

Navigation